| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 5
Volume 50 Number 4
Volume 50 Number 3
Volume 50 Number 2
Volume 50 Number 1
Volume 49 Number 6
Earlier issues
Back

Research Article

ScienceAsia 29 (2003): 181-188 |doi: 10.2306/scienceasia1513-1874.2003.29.181

Structure and Dynamics of SARS Coronavirus Proteinase: The Primary Key to the Designing and Screening for Anti-SARS Drugs

Vannajan Sanghiran Leea,b,Kitiyaporn Wittayanarakla,Vudhichai Parasaka, Pornthep Sompornpisuta,Wason Chantratitac,Chak Sangmad, Sornthep Vannaratf, Piyawut Srichaikulf, Supa Hannongbuad, Patchreenart Saparpakornd, Witcha Treesuwand, Ornjira Aruksakulwonga,Ekawat Pasomsubc, Siriporn Promsina, Daungmanee Chuakheawdand Supot Hannongbuaa,*


ABSTRACT: Structure and dynamics of SARS coronavirus (SARS-CoV) proteinase have been investigated using molecular dynamics (MD) simulation technique. The simulations were carried out under the NPT ensemble at 298 K and 1 atm, for free enzyme in both monomer and dimer forms and the monomer-inhibitor complex. The systems were observed to reach equilibrium after 200 ps. Enzyme conformation and its structural changes were monitored in terms of root mean square displacement of all 306 amino acid residues. The results show, as expected, that the proteinase in complex form is, in average, less flexible than the free form. Interest is centered on the two regions, at N-termini (residues 1-2) and around the active site (residues 56-62), in which the flexibilities in complex form is lower than those in free form. This behavior is supposed to facilitate the binding between enzyme and substrate. With the obtained MD structure, molecular dockings have been carried out in order to search for potent SARS-CoV proteinase inhibitors. Preliminary results show that among sixteen antiviral drugs taken from the NCI database, four of them with trade-name Nevirapine, Glycovir, Virazole, and Calanolide A, are observed to fit well in the active site of the SARS-CoV proteinase.

Download PDF


a Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
b Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.
c Virology and Molecular Microbiology, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
d Department of Chemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.
f High Performance Computing Research and Development Division, National Electronics and Computer Technology Center, Thailand Science Park, 112 Pahonyothin Road, Klong 1, Klong Luang, Pathumthani 12120, Thailand.

* Corresponding author, E-mail: supot.h@chula.ac.th

Received 3 Jun 2003, Accepted 30 Jun 2003